MOTS-c for MMA and Combat Sports: Dosing Protocol, Evidence, and Recovery Timeline

Print or save as PDFOpens the printable question sheet and your print dialog. No sign-up.

Is there a MOTS-c dosing protocol for fighters?

No study has tested a MOTS-c dosing protocol in people. FDA's July 2026 evaluation searched PubMed, Embase, the Cochrane library and other sources and identified no clinical study in which MOTS-c was given to a human [1]. The 12 papers the nominator submitted were not clinical studies [1].

Two numbers do appear in the regulatory record. The uses nominated for compounding were insulin resistance, obesity, osteoporosis, vascular calcification, muscle and fat metabolism and longevity, submitted as 5 mg and 10 mg subcutaneous injections [1]. Those are nominations for pharmacy compounding, not tested regimens — nobody has measured what either dose does in a person.

Rodent doses cannot fill the gap. Mouse work used 0.5 to 15 mg/kg, and FDA states those cannot be converted into human doses [1]. FDA also found no pharmacokinetic data for MOTS-c in humans or in live animals; the single kinetic observation is that the peptide is broken down quickly in human blood in vitro, which raises the question whether an injection can produce active levels at all [1]. The amount to inject, the route and the frequency in people are unmeasured.

What the research actually measured

Lee 2015 (Cell Metabolism). The paper that named the peptide described a short open reading frame within the mitochondrial 12S rRNA encoding a 16-amino-acid peptide [3]. In mice, MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity, with skeletal muscle as the main target and AMPK activated through inhibition of the folate cycle [3]. Mouse study only.

Reynolds 2021 (Nature Communications). In young (2-month), middle-aged (12-month) and old (22-month) mice, MOTS-c injection improved physical performance, and intermittent treatment begun late in life (23.5 months, three times weekly) increased physical capacity and healthspan [4]. In one mouse study, a late-life schedule of 15 mg/kg three times weekly lengthened median lifespan from 912 to 970 days [1]. The human portion of the Reynolds paper measured only that exercise raises the body's own MOTS-c in skeletal muscle and in circulation; participants were not given the peptide [4].

von Walden 2021 (Journal of Applied Physiology). Thirty healthy adults were randomized to endurance exercise (n=10, 45 minutes cycling at 70% of estimated VO2max), resistance exercise (n=10) or control (n=10) [5]. Circulating MOTS-c showed only a trend to rise after endurance exercise and was not related to fitness [5]. Again, nobody received MOTS-c.

Fuku 2015 (Aging Cell). A hypothesis paper proposing that the m.1382A>C variant in the MOTS-c gene, specific to Northeast Asian populations, may help explain Japanese longevity — a genetic epidemiology idea, not a drug trial [6].

What about recovery time, head impact and weight cuts?

No recovery timeline has been established for a fighter using MOTS-c. The performance results that get quoted come from mice, and the human studies above measured only the body's own peptide, not injections [4][5].

Head-impact protection and weight-cut support have no measured outcome in people. The mechanism proposed for the peptide — AMPK signaling with reduced one-carbon (folate) metabolism — comes from cell and rodent work, and FDA says the molecular targets are unknown [1][3].

What is known about safety in people?

FDA's adverse-event database search through March 9, 2025 found no MOTS-c reports. With no human exposure data by any route and no animal toxicity studies, its safety in people remains unknown [1]. FDA's stated concern for injected peptides is immunogenicity — an immune reaction to aggregates and peptide-related impurities — and MOTS-c has no immunogenicity data [1][7].

Anti-doping: MOTS-c is named on the WADA list

WADA's Prohibited List places MOTS-c in S4.4.1, metabolic modulators — activators of AMP-activated protein kinase — alongside AICAR [2]. It is prohibited at all times, in and out of competition, and S4.4 substances are non-Specified Substances [2]. It is on the 2026 List, in force since January 1, 2026, and remains on the 2027 List [2][8]. FDA notes it was already named on the 2024 List [1].

Regulatory status: what the votes and the draft policy do and do not do

MOTS-c is not an FDA-approved drug and is not a component of one; FDA's July 2026 review found no USP or National Formulary monograph, no listing in the European or Japanese pharmacopeias, and no product authorized by the European Medicines Agency [1]. It sits in the nominated-but-withdrawn table on FDA's page for bulk substances that may raise significant safety risks; FDA's concerns include that it has not identified any human exposure data on drug products containing MOTS-c by any route, that important safety information is missing, and that injectable peptides may pose immunogenicity risk from aggregation and impurities [7]. Removal from category 2 was not a finding that it is safe [7]. It appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians, and not on FDA's list for outsourcing facilities; FDA's category 1 policy does not cover it [9][10][11].

The Pharmacy Compounding Advisory Committee reviewed MOTS-c on July 23, 2026 and voted in favor of adding it to the bulks list, against the recommendation of FDA staff, who proposed that neither the free base nor the acetate be added [12][1]. That vote is advice only; MOTS-c is not on the list, and adding it requires formal rulemaking [13].

HHS's draft enforcement-discretion policy for six peptides, filed October 28, 2026, names MOTS-c and covers the acetate by subcutaneous or intramuscular injection [13][14]. HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with it when the policy's conditions are met, such as a single active ingredient and a patient-specific prescription [13]. The notice states that it does not establish any rights for any person and is not binding on HHS or the public, and it is neither an approval nor a listing [13]. Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness or quality before marketing [15].